Presentation will highlight lead clinical candidate FMP374, a novel dual-acting NMDAR modulator advancing toward IND-enabling studies for TRD HEIDELBERG, Germany,…
Oslo, Norway, 12th of February 2026 Vistin Pharma ASA (VISTN) today announces the financial results for the fourth quarter and…
MUMBAI, India, Feb. 9, 2026 /PRNewswire/ -- Made in India, written by Sundeep Khanna and Manish Sabharwal, traces three remarkable…
February 06, 2026 16:01 ET | Source: NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI, Feb. 06, 2026 (GLOBE NEWSWIRE)…
January 27, 2026 17:10 ET | Source: BridgeBio Pharma, Inc. PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- In…
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia and…
Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market presenceNext-generation BTK protein degrader APG-3288 receives…
- Rapidly transforming into a leading global biopharma company January 09, 2026 18:01 ET | Source: Ascendis Pharma COPENHAGEN, Denmark,…
January 05, 2026 11:05 ET | Source: Zealand Pharma Press release – No. 1 / 2026 Zealand Pharma to present…
December 31, 2025 11:05 ET | Source: Zealand Pharma Company announcement – No. 27 / 2025 Total number of shares…